Skip to main content
BTMD
NASDAQ Life Sciences

Executive Chairman Marc Beer Buys $202K of Biote Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare Facility Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.55
Mkt Cap
$50.485M
52W Low
$1.27
52W High
$3.62
52W Position info
22% above low
Off High info
57% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

BTMD sits 22% above its 52-week low of $1.27.

Summary

Executive Chairman Marc Beer bought $202K of Biote stock on the open market, signaling insider confidence despite recent weak results.


Key Events · Ownership and Investor Activity · BTMD

  • Executive Chairman Buys $202K

    Marc Beer purchased 131,950 shares at $1.53-$1.55 per share on August 10-11, 2026, totaling $202,204.

  • Post-Transaction Holdings

    Beer's direct holdings increased to 239,744 shares after the purchase.

  • Context: Recent Weak Results

    The purchase follows Biote's Q2 net loss of $7.4M, revenue decline of 9.5%, and a material weakness disclosure on August 5-7, 2026.


Analysis · BTMD · Life Sciences

Executive Chairman Marc Beer purchased 131,950 shares for $202,204 at $1.53-$1.55 per share on August 10-11, 2026. This is a real-money open-market purchase by a key insider, not an option exercise or grant. The buy comes just days after Biote reported a Q2 net loss of $7.4M, slashed full-year guidance, and disclosed an unremediated material weakness in internal controls. Beer's purchase is a notable vote of confidence in the company's turnaround prospects, though the dollar amount is modest relative to the company's market cap.

How filings like this one have moved

In the 30 days to Aug 23, 2026, 29.5% of the 2875 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BTMD was trading at $1.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.5M. The 52-week trading range was $1.27 to $3.62. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BTMD - Latest Insights

BTMD
Aug 07, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.53
Real-time Price: $1.60 info
Change: +$0.0746 (+5%) info
Market Cap: $57.843M info
BTMD
Aug 05, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.97
Real-time Price: $1.60 info
Change: -$0.370 (-19%) info
Market Cap: $57.843M info
BTMD
Jun 17, 2026, 4:05 PM EDT
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $2.27
Real-time Price: $1.60 info
Change: -$0.670 (-30%) info
Market Cap: $57.843M info
BTMD
Jun 02, 2026, 5:17 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.15
Real-time Price: $1.60 info
Change: -$0.550 (-26%) info
Market Cap: $57.843M info
BTMD
May 11, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.21
Real-time Price: $1.60 info
Change: -$0.610 (-28%) info
Market Cap: $57.843M info